Compare PGEN & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | NEOG |
|---|---|---|
| Founded | 1998 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2013 | 1995 |
| Metric | PGEN | NEOG |
|---|---|---|
| Price | $6.39 | $12.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $13.65 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 4.6M | 4.2M |
| Earning Date | 11-12-2026 | 10-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.20 |
| EPS | ★ 0.03 | N/A |
| Revenue | $230,981,000.00 | ★ $870,400,000.00 |
| Revenue This Year | $2,365.68 | $1.73 |
| Revenue Next Year | $85.75 | N/A |
| P/E Ratio | $220.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.04 | $5.37 |
| 52 Week High | $8.98 | $14.26 |
| Indicator | PGEN | NEOG |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 47.66 |
| Support Level | $6.08 | $11.25 |
| Resistance Level | $7.44 | $12.55 |
| Average True Range (ATR) | 0.44 | 0.69 |
| MACD | -0.17 | -0.06 |
| Stochastic Oscillator | 2.37 | 39.08 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Neogen Corp is develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Its Food Safety segment consists mainly of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. It also have products to determine food quality and nutritional components. Its segments are Food, Animal safety. Majority of revenue comes from Food Safety. It has presence in United states, and International market.